Logo
D

Delphinus Medical Technologies, Inc.

59 employees

Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Called SoftVue™, and featuring proprietary TriAD™ (triple acoustic detection) technology, the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. This is something no other ultrasound system, currently available, can do. SoftVue has received 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Formed in 2010 as a spin-out of Karmanos Cancer Institute in Detroit, MI, Delphinus is committed to creating improved imaging methods that assist medical professionals better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, and without concern of radiation or discomfort.

Investor insights

Funding rounds participated in

$12M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2010

Funding rounds raised

Total raised

$12M

from 1 investors over 1 rounds

D

Delphinus Medical Technologies, Inc. raised $12M on September 22, 2023

Investors: Trinity Capital

FAQ